Time BioVentures

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification. Its protein interrogation powered by nanoneedles enables early disease detection, prognostic monitoring, and biomarker discovery on a single chip. .

DeepSight™ Technology is revolutionizing diagnostic medical imaging by taking the safest, fastest, most affordable, and most accessible imaging modality and delivering a quantum leap in performance